Janney Capital Management Decreased Att (T) Holding By $32.37 Million; Dermira (DERM) SI Increased By 5.79%

April 17, 2018 - By David Stenberg

Dermira, Inc. (NASDAQ:DERM) Logo

Janney Capital Management Llc decreased Att Inc (T) stake by 97.74% reported in 2017Q4 SEC filing. Janney Capital Management Llc sold 851,902 shares as Att Inc (T)’s stock declined 10.37%. The Janney Capital Management Llc holds 19,666 shares with $764,000 value, down from 871,568 last quarter. Att Inc now has $230.32B valuation. The stock decreased 0.51% or $0.18 during the last trading session, reaching $35.46. About 9.69 million shares traded. AT&T Inc. (NYSE:T) has declined 15.88% since April 17, 2017 and is downtrending. It has underperformed by 27.43% the S&P500.

Dermira Inc (NASDAQ:DERM) had an increase of 5.79% in short interest. DERM’s SI was 4.44 million shares in April as released by FINRA. Its up 5.79% from 4.19 million shares previously. With 1.20 million avg volume, 4 days are for Dermira Inc (NASDAQ:DERM)’s short sellers to cover DERM’s short positions. The SI to Dermira Inc’s float is 14.16%. The stock increased 1.65% or $0.14 during the last trading session, reaching $8.64. About 726,374 shares traded. Dermira, Inc. (NASDAQ:DERM) has declined 77.97% since April 17, 2017 and is downtrending. It has underperformed by 89.52% the S&P500.

Among 9 analysts covering Dermira Inc (NASDAQ:DERM), 6 have Buy rating, 1 Sell and 2 Hold. Therefore 67% are positive. Dermira Inc had 26 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was maintained by Cantor Fitzgerald with “Buy” on Thursday, February 22. Guggenheim downgraded the shares of DERM in report on Tuesday, March 6 to “Neutral” rating. As per Tuesday, December 12, the company rating was maintained by Mizuho. Citigroup upgraded Dermira, Inc. (NASDAQ:DERM) on Friday, December 18 to “Buy” rating. The company was maintained on Tuesday, November 7 by Leerink Swann. The rating was maintained by Needham on Wednesday, May 11 with “Buy”. The rating was maintained by Needham on Friday, September 15 with “Buy”. The firm has “Buy” rating by Mizuho given on Thursday, September 7. The firm has “Buy” rating given on Wednesday, March 16 by Citigroup. On Monday, November 6 the stock rating was maintained by Cantor Fitzgerald with “Buy”.

Investors sentiment decreased to 1.27 in 2017 Q4. Its down 0.76, from 2.03 in 2017Q3. It dived, as 16 investors sold Dermira, Inc. shares while 35 reduced holdings. 25 funds opened positions while 40 raised stakes. 38.81 million shares or 5.56% less from 41.09 million shares in 2017Q3 were reported. Credit Suisse Ag has 0% invested in Dermira, Inc. (NASDAQ:DERM) for 38,705 shares. Parametric Portfolio Limited Co stated it has 0% of its portfolio in Dermira, Inc. (NASDAQ:DERM). Schwab Charles Mgmt Inc holds 0% or 180,235 shares. Gp One Trading L P has invested 0% in Dermira, Inc. (NASDAQ:DERM). 45,304 are owned by Sabby Management Lc. Wells Fargo Mn holds 0% of its portfolio in Dermira, Inc. (NASDAQ:DERM) for 24,848 shares. Millennium Mgmt Ltd Liability Corporation stated it has 901,981 shares or 0.03% of all its holdings. 3.51 million were reported by Nea Limited Liability Corp. United Automobile Association has 22,268 shares for 0% of their portfolio. Eventide Asset Management Limited Liability Co invested in 0.18% or 124,000 shares. State Street holds 0% or 830,962 shares in its portfolio. Invesco Ltd reported 0.01% of its portfolio in Dermira, Inc. (NASDAQ:DERM). Price T Rowe Associate Md stated it has 2.53 million shares. Blackrock owns 3.89M shares. Benjamin F Edwards Inc stated it has 2,975 shares or 0.01% of all its holdings.

Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the United States. The company has market cap of $361.34 million. The companyÂ’s late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne. It currently has negative earnings. It has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia.

Since December 13, 2017, it had 0 insider purchases, and 10 insider sales for $1.01 million activity. Shares for $82,011 were sold by BAUER EUGENE A on Monday, December 18. Another trade for 5,000 shares valued at $137,566 was sold by WIGGANS THOMAS G. Cohen David E sold $16,818 worth of Dermira, Inc. (NASDAQ:DERM) on Tuesday, January 2. Griffith Christopher M. sold $499,354 worth of stock.

Among 31 analysts covering AT&T Inc. (NYSE:T), 12 have Buy rating, 1 Sell and 18 Hold. Therefore 39% are positive. AT&T Inc. had 78 analyst reports since July 27, 2015 according to SRatingsIntel. The stock of AT&T Inc. (NYSE:T) earned “Neutral” rating by Moffett Nathanson on Tuesday, May 30. The rating was maintained by Scotia Capital on Tuesday, January 30 with “Hold”. The rating was maintained by Robert W. Baird with “Buy” on Wednesday, September 20. The firm earned “Sector Perform” rating on Thursday, January 26 by RBC Capital Markets. SunTrust maintained the shares of T in report on Thursday, February 1 with “Hold” rating. KeyBanc Capital Markets maintained the shares of T in report on Wednesday, October 11 with “Hold” rating. The stock has “Equal-Weight” rating by Morgan Stanley on Wednesday, September 27. The company was maintained on Friday, July 14 by Barclays Capital. On Wednesday, September 2 the stock rating was upgraded by Citigroup to “Buy”. The firm has “Outperform” rating by Robert W. Baird given on Monday, December 12.

Investors sentiment decreased to 0.91 in 2017 Q4. Its down 0.26, from 1.17 in 2017Q3. It dived, as 67 investors sold T shares while 714 reduced holdings. 125 funds opened positions while 589 raised stakes. 3.09 billion shares or 7.58% less from 3.34 billion shares in 2017Q3 were reported. Waters Parkerson Ltd Limited Liability Company accumulated 1.24% or 378,115 shares. Carret Asset Ltd Liability holds 1.15% or 189,706 shares. Sii Invs Wi reported 80,877 shares or 0.33% of all its holdings. Alphamark Advsrs Ltd Limited Liability Company has invested 0.13% in AT&T Inc. (NYSE:T). Gw Henssler And Assocs Ltd has invested 0.07% in AT&T Inc. (NYSE:T). Paragon Capital Limited Liability Corp reported 20,746 shares. Rice Hall James And Limited Co stated it has 0.01% of its portfolio in AT&T Inc. (NYSE:T). Price T Rowe Associate Md reported 0.09% in AT&T Inc. (NYSE:T). Cim Mangement holds 0.4% of its portfolio in AT&T Inc. (NYSE:T) for 30,287 shares. 42,285 are held by Svcs Wi. Summit Securities Group Limited Com reported 0.21% in AT&T Inc. (NYSE:T). Hudson Valley Advisors Inc Adv reported 0.77% stake. M&T Financial Bank Corp holds 0.69% or 3.38M shares in its portfolio. Moreover, Smith Howard Wealth Mgmt Llc has 0.12% invested in AT&T Inc. (NYSE:T) for 6,636 shares. Wells Fargo & Company Mn holds 0.58% or 51.44M shares in its portfolio.

Dermira, Inc. (NASDAQ:DERM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 David Stenberg

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: